– Allowance strengthens company's intellectual property estate and extends motixafortide patent protection in the U.S. through December 2041 – TEL AVIV, Israel , Oct.
16, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has received a Notice of Allowance from the U.S.
Patent and Trademark Office (USPTO) for a patent, titled, "COMPOSITION OF BL-8040," which covers the composition of motixafortide (APHEXDA®/BL-8040). The patent strengthens BioLineRx's robust intellectual property (IP) estate and extends its patent protection on motixafortide in the U.S.
through December 2041 . "We are very pleased to significantly strengthen our motixafortide IP with this key Composition of Matter patent that, among other things, extends our protection on this drug substance through December 2041 ," stated Philip Serlin , Chief Executive Officer of BioLineRx. "We believe this allowance reflects the USPTO's acknowledgment of the unique attributes of motixafortide that make it a significant advancement among mobilization agents for multiple myeloma patients undergoing autologous stem cell transplantation, as well as the other high-need indications in which it is being investigated, including pancreatic cancer and gene therapies for patients with sickle cell disease (SCD).
" In addition to a broad range of U.S. and international patents covering various a.